SynthesisFrontiers in pharmacology2025
Comparison of multiple doses of corticosteroids in Kawasaki disease: a Bayesian network analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic reprogramming rewires aberrant immune responses to drive endothelial dysfunction in Kawasaki disease: a narrative review.Translational pediatrics · 2026Review
- Development and validation of a novel interpretable machine learning model integrating immune-inflammatory indicators for intravenous immunoglobulin resistance in Kawasaki disease.Translational pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kawasaki disease (KD) is a leading cause of acquired heart disease in children, with coronary artery lesion (CAL) as a major complication. Although intravenous immunoglobulin (IVIG) remains the cornerstone of therapy, corticosteroids continue to play an important role in the management of IVIG-resistant, high-risk, or severe Kawasaki disease. Nevertheless, the optimal dosing strategies and differential therapeutic effects of corticosteroids in children with distinct clinical subtypes of KD remain poorly understood, particularly in those at highest risk. Methods: We conducted a Bayesian network meta-analysis of five regimens: intravenous immunoglobulin alone (IVIG-alone), medium-dose methylprednisolone alone (MDMP-alone), high-dose methylprednisolone alone (HDMP-alone), IVIG-plus-low-dose methylprednisolone (IVIG-plus-LDP), and IVIG-plus-HDMP. Data from randomized controlled trials (RCTs) through December 2024 were included. Results: IVIG-plus-HDMP ranked highest for preventing treatment resistance and reducing fever in initial and refractory KD [Surface Under the Cumulative Ranking Curve (SUCRA) 0.79]. IVIG-plus-LDP had the highest probability of reducing coronary artery dilation (CAD) incidence (SUCRA 0.89). Corticosteroid-related side effects (e.g., bradycardia, hypertension) were mild, transient, and reversible across all regimens, with no severe adverse events reported. Conclusion: IVIG-plus-HDMP is the most effective therapy for acute symptom control in KD, particularly in high-risk or IVIG-resistant cases, while IVIG-plus-LDP appears superior for long-term prevention of coronary complications in the general KD population. Treatment selection should be individualized based on patient risk profile and treatment priorities, balancing rapid symptom management against long-term coronary outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022339937.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.